Ipca Labs Q3 Results: Profit up 31%, margin expands as domestic and export sales grow

Ipca Laboratories reported a strong set of numbers for the quarter ended December 31, 2025, with profit growth outpacing revenue expansion and margins showing improvement.

Net profit rose 31.5% year-on-year to ₹326.3 crore in Q3 FY26, compared with ₹248 crore in the corresponding period last year. Revenue increased 6.6% to ₹2,392.5 crore from ₹2,245.4 crore a year earlier.

Operating performance strengthened during the quarter. EBITDA grew 15.2% year-on-year to ₹533.7 crore from ₹463.4 crore, while

EBITDA margin expanded to 22.3% from 20.6% in the year-ago period, reflecting improved operational efficiencies and business mix.

On the segmental front, Indian formulations income rose 12% to ₹984 crore, underlining steady traction in the domestic market. Export income also grew 13% to ₹770.49 crore, supporting overall revenue growth during the quarter.

Following the earnings announcement on Friday, February 13, shares of Ipca Laboratories were trading at ₹1,487.95 apiece, up ₹12.55 or 0.85% on the NSE as of 01:48 PM.

Also Read: Info Edge posts mixed Q3 results: Profit slips 14% sequentially, revenue and margins improve

Ipca is a fully integrated pharmaceutical company with a strong focus on exports. It operates across the pharmaceutical value chain, manufacturing both Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs), with a vertically integrated business model.